title: Role of serotonin 5-HT2A receptors in the development of cardiac hypertrophy in response to aortic constriction in mice.
abstract: Serotonin, in addition to its fundamental role as a neurotransmitter, plays a critical role in the cardiovascular system, where it is thought to be involved in the development of cardiac hypertrophy and failure. Indeed, we recently found that mice with deletion of monoamine oxidase A had enhanced levels of blood and cardiac 5-HT, which contributed to exacerbation of hypertrophy in a model of experimental pressure overload. 5-HT2A receptors are expressed in the heart and mediate a hypertrophic response to 5-HT in cardiac cells. However, their role in cardiac remodeling in vivo and the signaling pathways associated are not well understood. In the present study, we evaluated the effect of a selective 5-HT2A receptor antagonist, M100907, on the development of cardiac hypertrophy induced by transverse aortic constriction (TAC). Cardiac 5-HT2A receptor expression was transiently increased after TAC, and was recapitulated in cardiomyocytes, as observed with 5-HT2A in situ labeling by immunohistochemistry. Selective blockade of 5-HT2A receptors prevented the development of cardiac hypertrophy, as measured by echocardiography, cardiomyocyte area and heart weight-to-body weight ratio. Interestingly, activation of calmodulin kinase (CamKII), which is a core mechanism in cardiac hypertrophy, was reduced in cardiac samples from M100907-treated TAC mice compared to vehicle-treated mice. In addition, phosphorylation of histone deacetylase 4 (HDAC4), a downstream partner of CamKII was significantly diminished in M100907-treated TAC mice. Thus, our results show that selective blockade of 5-HT2A receptors has beneficial effect in the development of cardiac hypertrophy through inhibition of the CamKII/HDAC4 pathway.
authors.affiliation: INSERM UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, BP 84225, 31432, Toulouse Cedex 4, France.
authors.forename: O
authors.initials: O
authors.lastname: Lairez
authors.forename: T
authors.initials: T
authors.lastname: Cognet
authors.forename: S
authors.initials: S
authors.lastname: Schaak
authors.forename: D
authors.initials: D
authors.lastname: Calise
authors.forename: C
authors.initials: C
authors.lastname: Guilbeau-Frugier
authors.forename: A
authors.initials: A
authors.lastname: Parini
authors.forename: J
authors.initials: J
authors.lastname: Mialet-Perez
mesh_terms: D000367:Age Factors; D000704:Analysis of Variance; D000818:Animals; D001011:Aorta / Q000473:pathology*; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2 / Q000235:genetics / Q000378:metabolism; D006332:Cardiomegaly / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D003251:Constriction, Pathologic / Q000150:complications; D004195:Disease Models, Animal; D004452:Echocardiography; D005464:Fluorobenzenes / Q000627:therapeutic use; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology*; D006439:Hemodynamics / Q000187:drug effects; D006655:Histone Deacetylases / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009206:Myocardium / Q000378:metabolism; D010880:Piperidines / Q000627:therapeutic use; D012333:RNA, Messenger / Q000378:metabolism; D044402:Receptor, Serotonin, 5-HT2A / Q000235:genetics / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000627:therapeutic use
chemical_list: D005464:Fluorobenzenes; D010880:Piperidines; D012333:RNA, Messenger; D044402:Receptor, Serotonin, 5-HT2A; D012702:Serotonin Antagonists; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; C498618:Hdac5 protein, mouse; D006655:Histone Deacetylases; C079049:volinanserin
references.citation: J Mol Cell Cardiol. 2009 Apr;46(4):518-25
references.pmid: 19167402
references.citation: Cardiovasc Drugs Ther. 1990 Jan;4 Suppl 1:73-6
references.pmid: 2149515
references.citation: Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8
references.pmid: 19542488
references.citation: J Mol Cell Cardiol. 2009 Apr;46(4):587-95
references.pmid: 19162038
references.citation: Circulation. 2004 Aug 24;110(8):969-74
references.pmid: 15302781
references.citation: Trends Mol Med. 2004 May;10(5):232-8
references.pmid: 15121050
references.citation: Circ Res. 2005 Aug 5;97(3):268-76
references.pmid: 16002744
references.citation: J Mol Cell Cardiol. 2011 Oct;51(4):468-73
references.pmid: 21276796
references.citation: Can J Physiol Pharmacol. 2008 Apr;86(4):180-9
references.pmid: 18418427
references.citation: Cardiovasc Drugs Ther. 1990 Jan;4 Suppl 1:81-4
references.pmid: 2149517
references.citation: Clin Sci (Lond). 2005 Jun;108(6):547-52
references.pmid: 15707387
references.citation: J Mol Cell Cardiol. 2012 Feb;52(2):502-10
references.pmid: 21820441
references.citation: J Pharmacol Exp Ther. 1996 May;277(2):968-81
references.pmid: 8627580
references.citation: J Mol Cell Cardiol. 2007 Dec;43(6):767-79
references.pmid: 17936780
references.citation: J Neural Transm (Vienna). 2007;114(6):823-7
references.pmid: 17473906
references.citation: Circ Res. 2009 Jan 2;104(1):113-23
references.pmid: 19023134
references.citation: Cardiology. 2009;113(4):277-86
references.pmid: 19270454
references.citation: Life Sci. 2006 Sep 27;79(18):1749-55
references.pmid: 16876202
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23
references.pmid: 15322733
references.citation: Hypertension. 2008 Aug;52(2):301-7
references.pmid: 18591460
references.citation: Biochem Biophys Res Commun. 2010 Jan 1;391(1):979-83
references.pmid: 20005206
references.citation: Neuropsychopharmacology. 2005 Dec;30(12):2205-15
references.pmid: 15886717
references.citation: Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2870-5
references.pmid: 14976250
references.citation: Cardiovasc Res. 2006 Nov 1;72(2):303-12
references.pmid: 16962085
references.citation: J Clin Invest. 2009 May;119(5):1230-40
references.pmid: 19381018